Global Gastric & Gastroesophageal Junction Adenocarcinoma Market Discussed & Forecast in New GlobalData Report Available at MarketPublishers.com23 Mar 2016 • by Natalie Aster
LONDON – Representing a majority of the world’s cancer cases, gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) holds a position of the 5th most diagnosed disease as well at the 3rd most common cause of death from cancer in the world. Chemotherapy-based therapies emerge to be key treatments for G/GEJAC, though targeted therapies have received approval over the recent years and are added to chemotherapy regimens.
As of 2014, sales for G/GEJAC stood at more than USD 1.12 billion across the 8 major markets (8MM). They are expected to increase to approximately USD 4.4 billion in 2024, demonstrating a CAGR of over 14.58 percent. The growth is expected to stem from approval and uptake of some premium-priced products.
Cyramza is set to become the dominant market player by the end of the forecast period, and its market share is forecast to be just under 40 percent.
New research report “PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024” prepared by GlobalData offers an up-close look at the global G/GEJAC marketplace. The study contains a 360-degree view of the disease: it covers etiology and pathophysiology, looks at staging and symptoms, prognosis and a quality of life. The report investigates epidemiology and canvasses management of the disease, paying special attention to top countries. The research study includes competitive assessment of this marketplace, focuses on unmet needs and opportunities. A pipeline assessment, valuable data on current and future players, investigation of market drivers and barriers are also available in the research report. Future market outlook is on hand in the study, too.
PharmaPoint: Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2024
Published: December, 2015
Price: US$ 10,995.00
More new reports by this publisher are available at GlobalData page.